Eli Lilly’s experimental once-daily pill orforglipron beat oral semaglutide on both blood sugar control and weight loss in a large phase 3 trial involving 1,698 adults with type 2 diabetes. The results, published in The Lancet, provide a rare head-to-head comparison between an oral small-molecule GLP-1 receptor agonist (orforglipron) and oral semaglutide and could reshape competition in a drug class dominated by injectable formulations like Ozempic and Wegovy. For millions of patients who struggle with needles or the strict dosing rules tied to existing oral options, the findings carry real practical weight.
ACHIEVE-3 Trial Design and Scale
The study, formally called ACHIEVE-3, was a randomized, open-label, non-inferiority trial conducted across multiple countries and clinical sites. It enrolled 1,698 participants whose type 2 diabetes was inadequately controlled with metformin alone, according to the trial registry (NCT06045221). Participants were randomly assigned to receive either once-daily oral orforglipron, also known by its research designation LY3502970, or oral semaglutide (semaglutide tablets). The trial used prespecified endpoints to measure glycemic control through HbA1c reduction and body weight change over the treatment period, with statistical testing designed to show that orforglipron was at least not worse than its comparator.
What makes ACHIEVE-3 unusual is its direct comparative structure. Most GLP-1 drug trials test a new agent against placebo or a non-GLP-1 comparator, leaving clinicians to infer relative performance across different studies. Pitting two oral GLP-1 drugs against each other in a large, multinational study gives clinicians and patients something they rarely get: a clean, apples-to-apples read on which pill works better in the same population. The open-label design means neither patients nor investigators were blinded to treatment assignment, which is a limitation worth weighing when interpreting subjective outcomes, though the primary endpoints of HbA1c and weight are objective lab measurements less susceptible to observer bias. As described in the detailed phase 3 report, investigators also tracked safety, tolerability, and treatment discontinuation to round out the benefit–risk profile.
Orforglipron Outperforms on Blood Sugar and Weight
On both of its primary measures, orforglipron came out ahead. The trial demonstrated that orforglipron produced greater reductions in HbA1c compared with oral semaglutide, meaning patients on the Eli Lilly drug achieved tighter blood sugar control over the study period. In the published analysis, the HbA1c reductions favored orforglipron, supporting a clinically meaningful difference rather than a purely numerical edge. In The Lancet report, the differences met prespecified statistical thresholds for superiority rather than merely non-inferiority, strengthening the argument that the newer pill offers a step up in performance.
On weight loss, the gap was similarly clear. According to coverage of the study in a major UK outlet, orforglipron-treated patients lost up to 8% of their body weight, while those on semaglutide lost roughly 5%, based on reporting from The Guardian. That roughly three-percentage-point difference in weight loss matters more than it might sound. For a 220-pound adult with type 2 diabetes, it translates to shedding about 17.6 pounds on orforglipron versus roughly 11 pounds on oral semaglutide. In a disease where even modest weight reduction improves insulin sensitivity, blood pressure, and lipid profiles, the clinical significance compounds over time. The trial was designed as a non-inferiority study, meaning its primary statistical goal was to prove orforglipron was at least as good as semaglutide; instead, the drug cleared that bar and showed outright superiority on both key endpoints, a stronger result than the trial’s own hypothesis required.
The Convenience Factor: No Fasting Required
Beyond raw efficacy numbers, orforglipron carries a practical advantage that could matter just as much in daily life. Oral semaglutide, currently marketed as Rybelsus, requires patients to take the pill on an empty stomach with no more than a plain glass of water, then wait at least 30 minutes before eating, drinking, or taking other medications. That fasting window is not optional; it is baked into the drug’s label because food and other liquids interfere with absorption. Orforglipron has no such fasting restrictions, as noted in coverage of the Lancet findings, allowing it to be taken without regard to meals.
This distinction sounds minor in a clinical summary but plays out very differently in real-world adherence. Patients with type 2 diabetes often take multiple medications, including metformin, blood pressure drugs, and statins, typically with breakfast. Semaglutide’s fasting rule forces a scheduling workaround that many patients find burdensome, and non-adherence to the dosing protocol reduces the drug’s effectiveness. By removing that barrier, orforglipron could deliver its trial-level results more reliably outside the controlled conditions of a study. For clinicians choosing between two oral GLP-1 options, the simpler dosing regimen adds a meaningful tiebreaker on top of the efficacy data, especially for patients who have struggled with complex medication schedules or who prioritize convenience when weighing treatment options.
Where Oral GLP-1 Drugs Still Fall Short
Even with orforglipron’s strong showing, the broader context of GLP-1 therapy puts these results in perspective. Oral semaglutide has already been shown to produce less weight loss than its injectable counterparts, the injected versions sold as Ozempic and Wegovy, as discussed in the broader reporting and commentary around oral versus injectable semaglutide. Orforglipron may narrow that gap in this type 2 diabetes population, but it does not necessarily close it entirely. Patients seeking the maximum possible weight reduction, particularly those with obesity but without diabetes, may still find injectable formulations deliver more dramatic results. The ACHIEVE-3 trial focused on adults with type 2 diabetes inadequately controlled on metformin, so its findings cannot be automatically extrapolated to all populations who might be interested in GLP-1 therapy, such as younger patients, those with advanced kidney disease, or people using these drugs primarily for obesity management.
There are also the familiar class-wide issues to consider. Gastrointestinal side effects like nausea, vomiting, and diarrhea remain common with GLP-1 receptor agonists, and while the ACHIEVE-3 data suggest orforglipron’s tolerability is broadly in line with expectations, some patients will discontinue therapy because of these problems. Long-term safety, particularly around rare risks, will require follow-up beyond the timeframe of the current trial. Cost and insurance coverage will further shape real-world uptake: even a more effective and convenient pill may see limited use if payers favor cheaper injectables or impose strict prior authorization. As health systems weigh the evidence, the ACHIEVE-3 results position orforglipron as a compelling new entrant in the oral GLP-1 space, but not a cure-all for the clinical and economic challenges that surround diabetes and obesity treatment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
